Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapeOX + Bevacizumab + Pembrolizumab as Neoadjuvant Therapy for MSS Locally Advanced Rectal Cancer
NCT05585814Phase 2Active, not recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and bevacizumab in rectal cancer, sponsored by Shanghai Changzheng Hospital. Primary endpoints: R0 resection rate at 15 weeks, Pathological complete response rate at 15 weeks and 2 more. Started May 2023; status: active, not recruiting.
02
Drugs
pembrolizumabbevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05585814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585814.